BiotechTube

Vesitirim™ (Solifenacin)

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lower Urinary Tract Symptoms (LUTS)

Conditions

Lower Urinary Tract Symptoms (LUTS), Overactive Bladder (OAB)

Trial Timeline

Feb 1, 2012 → Dec 1, 2012

NCT ID
NCT01639794

About Vesitirim™ (Solifenacin)

Vesitirim™ (Solifenacin) is a pre-clinical stage product being developed by Astellas Pharma for Lower Urinary Tract Symptoms (LUTS). The current trial status is completed. This product is registered under clinical trial identifier NCT01639794. Target conditions include Lower Urinary Tract Symptoms (LUTS), Overactive Bladder (OAB).

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT01639794Pre-clinicalCompleted

Competing Products

20 competing products in Lower Urinary Tract Symptoms (LUTS)

See all competitors
ProductCompanyStageHype Score
JSP191Jasper TherapeuticsPhase 1
25
solifenacin succinate + tamsulosin hydrochloride + Placebo to solifenacin + Placebo to tamsulosinAstellas PharmaPhase 2
52
SolifenacinAstellas PharmaPre-clinical
23
Tamsulosin + SolifenacinAstellas PharmaApproved
85
Mirabegron + PlaceboAstellas PharmaPhase 2
52
tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)Astellas PharmaPhase 3
77
tamsulosin hydrochloride + solifenacin succinate + PlaceboAstellas PharmaPhase 2
52
Tamsulosin + SolifenacinAstellas PharmaApproved
85
Tamsulosin OCASAstellas PharmaApproved
85
DuloxetineShionogiPhase 3
77
Duloxetine + PlaceboShionogiPhase 3
77
AZD1656AstraZenecaPhase 1
33
Nirsevimab + PlaceboAstraZenecaPhase 3
77
RSVpreF + PlaceboPfizerPhase 3
76
GabapentinPfizerApproved
84
Erythropoiesis-stimulating agents (ESAs) + Luspatercept + Lenalidomide + Hypomethylating agents (HMAs) + Reb blood cell transfusionBristol Myers SquibbPre-clinical
22
ALX-0171 1.5 mg/kgSanofiPhase 2
51
ALX-0171 3.0 mg/kg + ALX-0171 6.0 mg/kg + ALX-0171 9.0 mg/kgSanofiPhase 2
51
ALX-0171 Dose 1 + ALX-0171 Dose 2 + PlaceboSanofiPhase 2
51
Placebo + Hydrocodone bitartrateUCBPhase 3
74

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85